Pharmacology of absence epilepsy

Trends in Pharmacological Sciences

Volumn 24, Issue 10, 2003, Pages 542-549

  Manning, Jon Paul A ^a   Richards, Douglas A ^a   Bowery, Norman G ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; ACETAZOLAMIDE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; MESUXIMIDE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; REMACEMIDE; SOLFOTON; TIAGABINE; TOPIRAMATE; TRIMETHADIONE; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE; BRAIN CORTEX; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEIZURE; SOMATOSENSORY CORTEX; THALAMUS;

EID: 0141987900     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2003.08.006     Document Type: Review

References (63)

1. Proposal for revised classification of epilepsies and epileptic syndromes Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 30:1989;389-399.
2. Crunelli V., Leresche N. Childhood absence epilepsy: genes, channels, neurons and networks. Nat. Rev. Neurosci. 3:2002;371-382.
3. Gibbs F.A., et al. The EEG in epilepsy and in conditions of impaired consciousness. Arch. Neurol. 34:1935;1134-1148.
4. Snead O.C. Basic mechanisms of generalised absence seizures. Ann. Neurol. 37:1995;146-157.
5. Sarkisian M.R. Overview of the current animal models for human seizure and epileptic disorders. Epilepsy Behav. 2:2001;201-216.
6. 2+ channel physiology and disease etiology. Cell. Mol. Neurobiol. 22:2002;103-120.
7. Danober L., et al. Pathophysiological mechanisms of genetic absence epilepsy in the rat. Prog. Neurobiol. 55:1998;27-57.
8. Coenen A.M.L., et al. Genetic models of absence epilepsy, with emphasis on the WAG/Rij strain of rats. Epilepsy Res. 12:1992;75-86.
9. Cortez M.A., et al. A model of atypical absence seizures: EEG, pharmacology, and developmental characterization. Neurology. 56:2001;341-349.
10. Avoli M., Gloor P. Interaction of the cortex and thalamus in spike wave discharges of feline generalised penicillin epilepsy. Exp. Neurol. 76:1982;196-217.
11. Gloor P., Fariello R.G. Generalized epilepsy: some of its cellular mechanisms differ from those of focal epilepsy. Trends Neurosci. 11:1988;63-68.
12. Penfield W.G., Jasper H.H. Highest level seizures. Assoc. Nerv. Ment. Dis. Proc. 26:1947;252-271.
13. Vergnes M., et al. Spontaneous spike and wave discharges in thalamus and cortex in a rat model of genetic petit mal-like seizures. Exp. Neurol. 96:1987;127-136.
14. Blumenfeld H., McCormick D.A. Corticothalamic inputs control the pattern of activity generated in thalamocortical networks. J. Neurosci. 20:2000;5153-5162.
15. Avanzini G., et al. Role of the thalamic reticular nucleus in the generation of rhythmic thalamo-cortical activities subserving spikes and waves. J. Neural Transm. 35:1992;85-95.
16. Vergnes M., et al. Enhancement of spike and wave discharges by GABAmimetic drugs in rats with spontaneous petit-mal-like epilepsy. Neurosci. Lett. 44:1984;91-94.
17. Mirsky A.F., et al. Petit mal epilepsy: a review and integration of recent information. J. Clin. Neurophysiol. 3:1986;179-208.
18. Liu Z., et al. Evidence for a critical role of GABAergic transmission within the thalamus in the genesis and control of absence seizures in the rat. Brain Res. 545:1991;1-7.
19. B neurotransmission in the control of absence seizures in the rat. Neuroscience. 48:1992;87-93.
20. Richards D.A., et al. Targeting thalamic nuclei is not sufficient for the full anti-absence action of ethosuximide in a rat model of absence epilepsy. Epilepsy Res. 54:2003;97-107.
21. D'Arcangelo G., et al. Thalamocortical oscillations in a genetic model of absence seizures. Eur. J. Neurosci. 16:2002;2383-2393.
22. Seidenbecher T., et al. Relations between cortical and thalamic cellular activities during absence seizures in rats. Eur. J. Neurosci. 10:1998;1103-1112.
23. Steriade M., Contreras D. Spike-wave complexes and fast components of cortically generated seizures. I. Role of neocortex and thalamus. J. Neurophysiol. 80:1998;1439-1455.
24. Meeren H.K., et al. Cortical focus drives widespread corticothalamic networks during spontaneous absence seizures in rats. J. Neurosci. 22:2002;1480-1495.
25. Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 58:1999;31-59.
26. Loscher W. Valproate enhances GABA turnover in the substantia nigra. Brain Res. 501:1989;198-203.
27. Johannessen C.U. Mechanisms of action of valproate: a commentatory. Neurochem. Int. 37:2000;103-110.
28. Johannessen C.U., Johannessen S.I. Valproate: past, present, and future. CNS Drug Rev. 9:2003;199-216.
29. McLean M.J., MacDonald R.L. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell-culture. J. Pharmacol. Exp. Ther. 237:1986;1001-1011.
30. Zona C., Avoli M. Effects induced by the antiepileptic drug valproic acid upon the ionic currents recorded in rat neocortical neurons in cell-culture. Exp. Brain Res. 81:1990;313-317.
31. Vreugdenhil M., Wadman W.J. Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis. Epilepsia. 40:1999;1512-1522.
32. Slevin J.T., Ferrara L.P. Chronic valproic acid therapy and synaptic markers of amino acid neurotransmission. Neurology. 35:1985;728-731.
33. Dixon J.F., Hokin L.E. The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4,5-triphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and bisphosphates. Proc. Natl. Acad. Sci. U. S. A. 94:1997;4757-4760.
34. Coulter D.A., et al. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann. Neurol. 25:1989;582-593.
35. Gomora J.C., et al. Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol. Pharmacol. 60:2001;1121-1132.
36. 1G) subunit by divalent cations and organic blockers. Neuropharmacology. 39:2000;1254-1266.
37. 2+ channels. Neuron. 31:2001;35-45.
38. Coulter D.A., et al. Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons. Neurosci. Lett. 98:1989;74-78.
39. Leresche N., et al. On the action of the anti-absence drug ethosuximide in the rat and cat thalamus. J. Neurosci. 18:1998;4842-4853.
40. Manning J.-P.A., et al. Ethosuximide has a powerful anti-absence action when bilaterally infused directly into the somatosensory cortex (S1) of the genetic absence epilepsy rat from Strasbourg (GAERS). Br. J. Pharmacol. 138:2003;2P.
41. Rogawski M.A., Porter R.J. Antiepileptic drugs - pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev. 42:1990;223-286.
42. Van Luijtelaar E.L.J.M., Coenen A.M.L. Effects of remacimide and its metabolite FPL 12495 on spike-wave discharges, electroencephalogram and behaviour in rats with absence epilepsy. Neuropharmacology. 34:1995;419-425.
43. Nehlig A., Boehrer A. Effects of remacemide in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS. Epilepsy Res. 52:2003;253-261.
44. Dufour F., et al. Metabolic approach of absence seizures in a genetic model of absence epilepsy, the GAERS: study of the leucine-glutamate cycle. J. Neurosci. Res. 66:2001;923-930.
45. Coulter D.A. Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in? J. Child Neurol. 12:(Suppl. 1):1997;S2-S9.
46. 2+ currents. Seizure. 10:2001;279-286.
47. Lukyanetz E.A., et al. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 43:2002;9-18.
48. Loscher W., et al. The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulate. Brain Res. 735:1996;208-216.
49. B receptor antagonists: potential new anti-absence drugs. J. Neural Transm. Suppl. 35:1992;179-188.
50. B antagonist, in the lethargic mouse, γ-hydroxybutyrate, and pentylenetetrazole models. J. Pharmacol. Exp. Ther. 274:1995;1399-1403.
51. B receptors in excitation and inhibition of thalamocortical cells. Trends Neurosci. 14:1991;16-21.
52. Kochen S., et al. Spike-and-wave complexes and seizure exacerbation caused by carbamazepine. Eur. J. Neurol. 9:2002;41-47.
53. Li X., et al. Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? J. Affect. Disord. 69:2002;1-14.
54. Williams R.S.B., et al. A common mechanism of action for three mood-stabilizing drugs. Nature. 417:2002;292-295.
55. Genton P. When anti-epileptic drugs aggravate epilepsy. Brain Dev. 22:2000;75-80.
56. Trudeau V., et al. Gabapentin in naïve childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J. Child Neurol. 11:1996;470-475.
57. Vossler D.G. Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin. Neurology. 46:1996;852-853.
58. B receptors: structure and function. Pharmacol. Rev. 54:2002;247-264.
59. Taylor C.P., et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 29:1998;233-249.
60. Panayiotopoulos C.P. Treatment of typical absence seizures and related epileptic syndromes. Paediatr. Drugs. 3:2001;379-403.
61. Llinas R.R., et al. Thalamocortical dysrhythmia: a neurological and neuropsychiatric syndrome characterized by magnetoencephalography. Proc. Natl. Acad. Sci. U. S. A. 96:1999;15222-15227.
62. Ritchie G.D., et al. Treatment of spontaneous and chemically induced EEG paroxysms in the Fischer-344 rat with traditional antiepileptic drugs or AED+CGP 35348 polytherapy. Prog. Neuropsychopharmacol. Biol. Psychiatry. 27:2003;847-862.
63. Panayiotopoulos C.P. A Clinical Guide to Epileptic Syndromes and their Treatment. 2002;Bladon Medical Publishing, Oxford.